Document is current
Any future updates will be listed below
-
Authors
Beauchemin, Melissa P.
Murphy-Banks, Rachel
Rodday, Angie Mae
Freyer, David R.
Miller, Kimberly A.
Fleisher, Emma
Ohlsen, Timothy J. D.
Linendoll, Nadine
Chan, Randall Y.
Crosswell, Howland E.
Roth, Michael E.
Parsons, Susan K.
-
Funding
Funding for this research was provided by:
National Center for Advancing Translational Sciences (KL2TR001874)
National Cancer Institute (P30CA014089, P30CA014089, P30CA016672)
Leukemia and Lymphoma Society (PHS9005-21)
- License Information
-
More Information
Article History
Received: 6 December 2024
Accepted: 18 June 2025
First Online: 25 June 2025
Declarations
:
: This study was reviewed and approved by the Tufts Health Sciences Institutional Review Board (IRB) in the fall of 2021 (STUDY 00001828), which served as the central study site. All participating recruitment site IRBs reviewed the protocol, and reliance agreements were executed as applicable by local IRB determination.
: Participants provided informed consent to the intervention study and optional interview at time of enrollment.
: The authors declare no competing interests.
